Bristol Myers Squibb Company (NYSE:BMY) Stock Has Average Price Target of $64.88 According to Analysts

Shares of Bristol Myers Squibb Company (NYSE:BMY) have been assigned an average rating of “Hold” from the thirty brokerages that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, sixteen have given a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $65.50.

A number of research firms recently issued reports on BMY. Daiwa Securities Group lifted their price target on Bristol Myers Squibb from $53.00 to $66.00 and gave the company a “neutral” rating in a report on Tuesday, August 4th. Cantor Fitzgerald lowered their price objective on shares of Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating for the company in a research report on Thursday, October 8th. Guggenheim reaffirmed a “buy” rating and issued a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. HSBC reiterated a “hold” rating and set a $65.00 target price (up from $60.00) on shares of Bristol Myers Squibb in a research report on Thursday, September 10th. Finally, Leerink Partners lowered shares of Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $73.00 to $59.00 in a report on Monday, October 5th.

Insider Buying and Selling at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.05% of the stock is currently owned by insiders.

Institutional Trading of Bristol Myers Squibb

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. lifted its position in Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares during the period. State Street Corp grew its position in shares of Bristol Myers Squibb by 7.3% during the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock worth $6,093,755,000 after buying an additional 7,192,724 shares during the period. Primecap Management Co. CA acquired a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Bristol Myers Squibb by 0.5% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company’s stock worth $1,315,984,000 after buying an additional 119,690 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of Bristol Myers Squibb by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company’s stock worth $1,137,847,000 after buying an additional 520,330 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Up 0.1%

NYSE BMY opened at $61.56 on Tuesday. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The stock’s 50 day moving average is $63.20 and its two-hundred day moving average is $59.79. The company has a market capitalization of $125.75 billion, a price-to-earnings ratio of 13.56, a PEG ratio of 0.31 and a beta of 0.19. Bristol Myers Squibb has a 1-year low of $42.52 and a 1-year high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The firm had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same period in the prior year, the company posted $1.46 earnings per share. The business’s revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts forecast that Bristol Myers Squibb will post 6.51 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Promising lung-cancer results: Iza-bren doubled median progression-free survival versus chemotherapy in previously treated EGFR-mutated non-small-cell lung cancer in the Phase 3 PANKU-Lung01 study. The results strengthen the potential of BMY’s pipeline to offset declining legacy-drug revenue. Iza-bren lung-cancer Phase 3 results
• Positive Sentiment: Additional oncology momentum: A Phase 3 breast-cancer study reportedly showed Iza-bren reduced disease-progression risk by as much as 38%, while a Phase 2 trial of BMY and BioNTech’s pumitamig plus docetaxel produced a 36.7% response rate in advanced non-small-cell lung cancer. These programs could broaden BMY’s growth-drug portfolio. BMY cancer breakthrough Pumitamig Phase 2 data
• Positive Sentiment: Analyst remains bullish: Piper Sandler maintained an “overweight” rating and still sees substantial potential upside, despite reducing its price target from $82 to $78. Piper Sandler BMY rating
• Neutral Sentiment: Q3 earnings focus: Investors are weighing growth from newer medicines and improved Eliquis guidance against declines in BMY’s legacy portfolio ahead of quarterly results. Analysts are also monitoring revenue, margins and other operating metrics. BMY Q3 earnings outlook
• Negative Sentiment: Patent-cliff risk persists: Investors remain concerned that patent expirations for two blockbuster drugs could create a significant revenue gap before new medicines fully mature, despite BMY’s low valuation and dividend appeal. BMY patent-cliff analysis
• Negative Sentiment: Cautious earnings sentiment: Erste Group issued a pessimistic earnings outlook, adding to broader sell-side caution around BMY’s growth rate and post-patent-cliff prospects.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.